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The CD146 (also known as MCAM, MUC-18, Mel-CAM) 
was initially reported on in 1987, as a protein crucial for 
melanoma invasion. Recently, it has been confirmed that 
CD146 is involved in progression and poor overall sur-
vival of many other cancers, including breast cancer. Im-
portantly, in independent studies, CD146 was reported 
to be a trigger of epithelial to mesenchymal transition in 
breast cancer cells. The goal of our current study was to 
verify possible involvement of an epigenetic mechanism 
behind regulation of the CD146 expression in breast 
cancer cells, as it has been previously reported for pros-
tate cancer. First, we analysed the response of breast 
cancer cells, varying in the initial CD146 mRNA and pro-
tein content, to an epigenetic modifier, 5-aza-2-deoxy-
cytidine, and subsequently the methylation status of 
CD146 gene promoter was investigated, using direct bi-
sulfite sequencing. We observed that treatment with a 
demethylating agent led to induction of CD146 expres-
sion in all analysed breast cancer cell lines, both at the 
mRNA and protein levels, which was accompanied by 
an elevated expression of selected mesenchymal mark-
ers. Importantly, CD146 gene promoter analysis showed 
aberrant CpG island methylation in 2 out of 3 studied 
breast cancer cells lines, indicating epigenetic regulation 
of the CD146 gene expression. In conclusion, our study 
revealed for the first time that aberrant methylation may 
be involved in expression control of CD146, a very po-
tent EMT inducer in breast cancer cells. Altogether, the 
data obtained may provide basis for novel therapies, as 
well as diagnostic approaches enabling sensitive and 
very accurate detection of breast cancer cells. 
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INTRODUCTION
Death of breast cancer patients is mainly caused by 
metastasis, transforming the locally confined disease into 
a disseminated and usually incurable one (Felipe Lima et 
al., 2016). Metastasis can be defined as spreading of can-
cerous cells into distinct organs, followed by formation 
of a secondary tumor site. At the molecular level, this 
process is accompanied by actin cytoskeleton rearrange-
ment and attenuation of cell-cell and cell-extracellular 
matrix adhesive interactions, which altogether resem-
bles the Epithelial to Mesenchymal Transition (EMT), 
a morphogenetic process observed during development 
(Brabletz et al., 2018; Nieto et al., 2016). EMT is driven 
by mesenchymal transcription factors, including Snail, 
Slug, Zeb, and Twist, which are responsible for altering 
the epithelial transcriptional profile into mesenchymal 
one (Nieto et al., 2016; Felipe Lima et al., 2016). Breast 
cancer cells undergoing EMT become highly motile and 
invasive, which is especially apparent in the most ag-
gressive estrogen–negative, progesterone-negative, hu-
man epidermal growth factor receptor-negative subtype 
(ER−/PR−/HER2−), defined as a triple-negative breast 
cancer (TNBC) (Khaled & Bidet, 2019; Felipe Lima et 
al., 2016). TNBC diagnosed patients have a relatively 
poor prognosis and cannot be subjected to endocrine 
therapy or therapies directed against human epidermal 
growth factor receptor type 2 (HER2) (Schneider et al., 
2008). Interestingly, recent publication and meta-analysis, 
covering a high number of solid tumors, revealed a sig-
nificant association of CD146 protein expression, EMT 
and poor survival of cancer patients (Zeng et al., 2017). 
Importantly, independent studies reported that CD146 is 
highly expressed in TNBC and in metastatic breast can-
cer, which is contrary to normal tissue and benign tu-
mors (de Kruijff et al., 2018; Garcia et al., 2007; Jang et 
al., 2015; Zabouo et al., 2009). Moreover, preclinical in 
vitro and in vivo studies revealed that aberrantly overex-
pressed CD146 is sufficient to induce acquisition of mes-
enchymal phenotype in breast cancer cells (Zeng et al., 
2012; Imbert et al., 2012). Nevertheless, although over-
expressed CD146 is considered an important oncogene 
in breast carcinogenesis, there is still lack of information 
about potential regulation of the CD146 gene expres-
sion in breast cancer cells. Despite the fact that CD146 
is overexpressed in cancer cells, its amplification or mu-
tation has been excluded so far (Wang & Yan, 2013). 
In the study presented here, by using breast cancer cell 
lines as a model, we revealed that CD146 gene promoter 
is aberrantly methylated in breast cancer cells and the 
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demethylating agent, 5-aza-2-deoxycytidine, can trigger 
its expression. According to our knowledge, this is the 
first study suggesting a role of epigenetics behind the 
CD146 expression in breast cancer cells. Noteworthy, 
this finding not only sheds new light on regulation of 
CD146 expression during breast carcinogenesis, but also 
provides an important rationale for novel therapeutic 
strategies in future. If confirmed with primary samples, 
it may contribute to a significant improvement of the di-
agnostic process, allowing early and very sensitive detec-
tion of breast cancer cells. 
MATERIALS AND METHODS
R2 Database and statistical analysis of publically 
available data. The R2 database (http://r2.amc.nl) is a 
simple to use website-related tool for analysis and data 
visualization created at the Department of Oncogenom-
ics in the Academic Medical Center (AMC) in Amster-
dam, Netherlands. It gives an opportunity to perform 
different analyses based on well annotated datasets. In 
case of the study presented here, we selected tool “Cor-
relate Genes” in the panel of 10 breast cancer data sets 
in order to check correlation between CD146 and the 
panel of mesenchymal markers. Bonferroni corrected 
p-value of the Spearman correlation coefficient was 
used to show that the panel of mesenchymal marker 
encoding genes significantly correlated with CD146 in 
breast cancer patients. Since the 9 mesenchymal markers 
were compared with CD146, p value below 0.0055 was 
considered as significant (0.05/9). The ten breast cancer 
data sets chosen for analysis included two sets (GSE7396 
and GSE46563) composed of only lymph node nega-
tive patients and eight data sets (GSE1456, GSE12276, 
GSE2109, GSE3494, GSE102484, GSE29271, 
GSE69031, GSE36771) in which lymph node negativ-
ity was not the criterion for patient selection. Since the 
number of genes correlated with CD146 was lower in 
data sets with confirmed lymph node negativity in com-
parison to other data sets, we applied cluster analysis 
(nearest neighbor, Euclidean distance) algorithm to verify 
if these two data set are indeed different from all the 
others (Statistica, TIBCO Software Inc.). 
For the purpose of analysis, the non-sig-
nificant Spearman correlation coefficient 
was set as zero.
Cell lines and cell culture. MCF7 and 
T47D breast cancer cell lines, as well as 
human fibroblast (Hs27) cells, were pur-
chased from the American Type Culture 
Collection (Rockville, MD, USA). MDA-
MB-231 breast cancer cell line was pur-
chased from Sigma-Aldrich (St. Louis, 
MO, USA). All cells were grown in RPMI 
1640 medium (Gibco Life Technology), 
supplemented with 10% fetal bovine se-
rum (FBS), (EURx, Gdansk, Poland), 
2 mmol/L L-glutamine and 100 units/
mL penicillin G and Streptomycin (Sig-
ma-Aldrich, St. Louis, MO, USA). For 
demethylation study, MCF7, T47D and 
MDA-MB-231 cells were cultured with 
and without 10 µM 5-aza-2-deoxycytidine 
(#PA-03-1241-P, Pol-AURA, Poland) for 
6 days, and on day 4 the cell culture me-
dia were exchanged for fresh ones, with 
and without 5-aza-2-deoxycytidine, respec-
tively.
RNA isolation and cDNA synthesis. 
Total RNA was isolated from harvested cells using Gene 
Matrix Universal RNA kit (EURx, Gdansk, Poland). Na-
noDrop ND-1000 Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA) was used to determine 
concentration and quality of the isolated RNA. Total 
RNA (1 µg) was used for cDNA synthesis according to 
the manufacturer’s protocol (EURx, Gdansk, Poland).
Reverse transcription polymerase chain reaction 
(RT-PCR). For PCR reaction, the Color OptiTaq PCR 
Master Mix (2x) (EURx, Gdansk, Poland) was used ac-
cording to the manufacturer’s protocol. Sequences of 
reverse and forward primers used in this study are pre-
sented in Table 1. For CD146, HPRT1, SNAI1, TWIST, 
ZEB1 and SNAI2, the PCR reactions were carried out 
as previously described (Dudzik et al., 2019). For CAD-
HERIN1 and CADHERIN2, the conditions were as fol-
lowing: initial denaturation at 95°C for 5 min; followed 
by 30 cycles: 30 s at 95°C, 30 s at 58°C and 30 s at 72°C; 
and final extension at 72°C for 10 min. For MMP2 and 
MMP9 the following conditions were applied: initial de-
naturation at 94°C for 3 min; followed by 30 cycles: 45 
s at 94°C, 60 s at 59°C and 60 s at 72°C; and final ex-
tension at 72°C for 5 min. PCR product was visualized 
on 1.5% agarose gel stained with ethidium bromide and 
photographed with Bio-Rad ChemiDoc™ XRS+ System 
(Bio-Rad, Hercules, CA, USA). HPRT1 was used as in-
ternal control to ensure equal sample loading. In case of 
MDA-MB-231 cells, the RT-PCR analysis of CD146 was 
performed according to a modified, adjusted PCR pro-
tocol in which 25 cycles were used instead of 30 cycles, 
whereas all other conditions remained unchanged. 
The CD146 and HPRT1 primers were manufactured 
by IBB PAN (Warsaw, Poland). All other primers were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
The images of the gels were captured using Bio-Rad 
ChemiDoc™ XRS+ System (Bio-Rad, Hercules, CA, 
USA) and subsequently analyzed by means of publicly 
available ImageJ software. All values were normalized to 
the HPRT1 signal. 
Western blot. The cells were lysed and protein con-
centration was determined as previously described 
(Kocemba-Pilarczyk et al., 2018). Protein lysates (30 µg) 
Table 1. Sequences of primers used for selected gene expression analyses. 
Gene Length (bp) Primer Sequences
CD146 438 forward 5'-CCAAGGCAACCTCAGCCATG-3’reverse 5’-CTCGACTCCACAGTCTGGGA-3’
HPRT1 504 forward 5’-TGGCGTCGTGATTAGTGATG-3’reverse 5’-TATCCAACACTTCGTGGGGT-3’
SNAI1 307 forward 5’-GGATCTCCAGGCTCGAAAGG-3’reverse 5’-CATTCGGGAGAAGGTCCGAG-3’
TWIST1 177 forward 5’-CCGTGGACAGTGATTCCCAG-3’reverse 5’-CCTTTCAGTGGCTGATTGGC-3’
ZEB1 140 forward 5’-TCCTCGAGGCACCTGAAGAGG-3’reverse 5’-CAGAGAGGTAAAGCGTTTATAGCC-3’
SNAI2 372 forward 5’-GCTACCCAATGGCCTCTCTC-3’reverse 5’-TTGCCGCAGATCTTGCAAAC-3’
CADHERIN 1 342 forward 5’-GCCAAGCAGCAGTACATTCTACACG-3’reverse 5’-GTCGTTCTTCACGTGCTCAAAATCC-3’
CADHERIN 2 370 forward 5’-GCGTTCCTGTTCCACTCATAGGAGG-3’reverse 5’-GTGCCATTAGCCAAGGGAATTCAGC-3’
MMP2 499 forward 5’-TGATGGAGAGGCAGACATCA-3’reverse 5’-ATACTTCTTGTCGCGGTCGT-3’
MMP9 98 forward 5’-CTGAGAACCAATCTCACCGACA-3’reverse 5’-AGATTTCGACTCTCCACGCA-3’
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were separated by SDS PAGE (10%), and subsequently 
blotted onto nitrocellulose membrane (Thermo Fisher 
Scientific, MA, USA). After blocking (5% non-fat dry 
milk), the proteins of interest were detected by the fol-
lowing primary antibodies: anti-CD146 (P1H12, #13475, 
Cell Signalling, Danvers, MA, USA, 1:500 in 5% BSA), 
anti-N-cadherin (#610920, BD Pharmigen, 1:1000 in 5% 
BSA), anti-E-cadherin (#610404, BD Pharmigen, 1:1000 
in 2% BSA), anti-Vimentin (#550513, BD Pharmigen, 
1:1000 in 5% BSA) and appropriate (anti-mouse or 
anti-rabbit) HRP-conjugated secondary antibodies (Cell 
Signalling Technology Inc; 1:2000 in 5% non-fat milk). 
Anti-beta-actin primary antibody (Clone AC-15, #A1978, 
Sigma-Aldrich, 1:10 000 in 5% non-fat milk) and HRP-
conjugated secondary antibody (Cell Signalling Technol-
ogy Inc; 1:5 000 in 5% non-fat dry milk) were used to 
ensure equal protein loading. The signal was visualized 
by chemiluminescent substrates of different sensitivities, 
depending on the protein of interest expression level. 
For low, moderate and high content of analyzed protein, 
the Signal Fire ™ Elite ELC Reagent (Cell Signaling Tech-
nology Inc), LumiGLO Reagent (Cell Signalling Tech-
nology Inc) and Amersham ECL™ Western Blotting De-
tection Reagents (GE, Healthcare, Chicago, ILL, USA) 
were used, respectively. Chemiluminescence intensity was 
recorded with Bio-Rad ChemiDoc™ XRS+ System (Bio-
Rad, Hercules, CA, USA). 
Immunofluorescent staining. Cells were washed 
with Dulbeco’s phosphate buffer saline (DPBS) and 
fixed in 4% paraformaldehyde for 20 minutes at room 
temperature. After incubation, the cells were rinsed with 
DPBS containing 0.1% Triton X-100 (Sigma-Aldrich) 
for 5 minutes, and subsequently blocked in 3% bovine 
serum albumin (BSA, Sigma-Aldrich) in DPBS without 
ions for 1 h at room temperature. Then, the cells were 
incubated with appropriate primary antibody diluted in 
3% BSA in DPBS for 24 h at 4°C. Antibodies were as 
follows: rabbit anti-E-cadherin antibody (1:200; ab15148; 
Abcam), mouse anti-vimentin (1:200, V9, sc-6260; San-
ta Cruze Biotechnology). The cells were washed with 
DPBS 5 times and then incubated with Hoechst (Sig-
ma-Aldrich), as well as secondary goat anti-rabbit or 
anti-mouse antibodies conjugated with Alexa Fluor 488 
(ThermoFisher) or Alexa Fluor 555 (ThermoFisher) di-
luted in 3% BSA in DPBS for 1h at room temperature 
in the dark. The results were analyzed with the IX70 mi-
croscope (Olympus Corporation, Tokyo, Japan).
Bisulfite sequencing. Genomic DNA was extracted 
from MCF7, T47D, MDA-MB-231 and Hs27 cells us-
ing GenElute Mammalian Genomic DNA Miniprep Kits 
(Sigma Aldrich, St. Louis, MO, USA) according to the 
manufacturer’s instructions. Concentration and quality 
of isolated DNA were assessed by means of NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE, USA). The DNA was modified, 
and bisulfite sequencing procedure was carried out as 
previously described (Dudzik et al., 2019). Primers for 
bisulfite-converted DNA were as following: forward 
(5'-GTTGTAAATTGGTTGTAAAGAAGAGTTG–3′), 
reverse (5′–CAACCTTCCCAAACCAAAAAC–3′), gen-
erating a product of 502 bp, which was cut out of the 
gel, purified according to the manufacturer’s instructions 
(Agarose Out DNA purification kit, EURx, Gdansk, Po-
land), and subsequently sequenced (Genomed, S.A, Po-
land). Primers were manufactured by Sigma-Aldrich (St. 
Louis, MO, USA). The CD146 gene sequence (11q23.3, 
NCBI/GRCh38.p12, 119305759-119317130) including 
its promoter was downloaded from the database of Na-
tional Centre for Biotechnology Information (NCBI). 
The CD146 gene promoter CpG island (cg 21096399, 
NCBI/GRCh38.p12, 119317381-119316788) encom-
passes exon 1, including transcriptional (NCBI/GRCh38.
p12, 119317130) and translational (NCBI/GRCh38.p12, 
119317101) start sites, as well as the fragment of 5’ up-
stream coding sequence (Kocemba et al., 2016), which al-
together is characteristic for genes that are transcription-
ally silenced by an epigenetic mechanism (Feltus et al., 
2003). The area of CpG island selected for methylation 
analysis (+238 to –162 in relation to the transcription 
start sites, TSS), containing representative 50 CpG sites 
(out of the 62 CpG dinucleotides present in the specific 
CpG island), covered exon 1 with transcriptional and 
translational start sites. 
RESULTS
The relation between CD146 and mesenchymal profile 
in breast cancer cell lines
In spite of a number of studies confirming the rela-
tionship between CD146 and tumor invasiveness, poor 
prognosis or mesenchymal features of breast cancer cells, 
a recent work by de Kruijff et al. questioned the exist-
ence of EMT-CD146 association in a group of analysed 
breast cancer patients (de Kruijff et al., 2018). Although 
these authors indeed reported CD146 as a prognostic 
factor for metastasis free and overall survival in a uni-
variable analysis, they did not find a correlation between 
CD146 and mesenchymal markers at the level of mRNA 
expression (de Kruijff et al., 2018). In order to perform 
an independent verification, we analysed the relation be-
tween CD146 expression and the panel of mesenchymal 
markers in 10 independent transcriptomic data sets of 
breast cancer patients. The patients’ data sets selected for 
this analysis included 2 data sets containing breast cancer 
patients with confirmed lymph node negativity (lymph 
node negative data sets) and 8 data sets in which patients 
with lymph node negative and positive status were com-
bined (non-lymph node negative data sets). As shown in 
Table 2, at least 6 out of 9 mesenchymal markers were 
significantly correlated with CD146 in non-lymph node 
negative data sets, whereas in lymph node negative data-
sets we have found only 2 mesenchymal markers cor-
related with CD146 in the GSE7396 data set, and only 
one (vimentin) correlated with CD146 in the GSE46563 
data set. In fact, vimentin was the only gene correlated 
Table 2. Correlation analysis between CD146 and nine selected 
mesenchymal markers in 10 independent transcriptomic data 
sets of breast cancer patients.
White rectangle indicates lack of significance, grey rectangle in-
dicates a significant Spearman correlation coefficient below 0.5, 
black rectangle indicates a significant Spearman correlation coef-
ficient above 0.5. Bonferroni corrected p-value below 0.0055 was 
considered as statistically significant.
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with CD146 in all analysed data sets, regardless of the 
lymph node status. In order to verify if two lymph node 
negative data sets are different from the others, cluster 
analysis was performed. This approach further confirmed 
that two lymph node negative data sets clustered to-
gether as being different from all the others. Thus, the 
results of our analysis clearly demonstrated, based on 
transcriptomic data, the existence of association between 
CD146 expression, mesenchymal profile and the pro-
gression of breast cancer.
The effect of 5-aza-2-deoxycytidine on expression of 
CD146 in breast cancer cell lines
In order to check whether CD146 expression is 
regulated at the transcriptional level by an epigenetic 
modifier, 5-aza-2-deoxycytidine, as it has been shown 
previously in prostate cancer cell lines (Dudzik et al., 
2019), two epithelial breast cancer cell lines (MCF7 
and T47D) (Dai et al., 2017) and a mesenchymal one 
(MDA-MB-231) (Dai et al., 2017) were cultured with 
and without 5-aza-2-deoxycytidine (10 μM) for 6 days, 
as previously described, followed by CD146 expression 
analysis at the mRNA and protein level. As expected, 
basal expression of CD146 was low in the MCF7 and 
T47D cancer cell lines with epithelial characteristics, and 
high in the MDA-MB-231 cell line with mesenchymal 
expression profile. As shown in Fig. 1, CD146 expres-
sion was apparently induced in the MCF7 and T47D 
cells, whereas in MDA-MB-231 its high basal expres-
sion disabled correct assessment of expression difference 
between the control and 5-aza-2-deoxycytidine treated 
cells. Thus, in order to verify if high CD146 expression 
in MDA-MB-231 is still further inducible, we performed 
an expression analysis according to an adjusted, modified 
PCR protocol, as described in the Materials and Meth-
ods section. Interestingly, in MD-MB-231, the CD146 
expression was also significantly induced, regardless of 
the high basal level and the mesenchymal characteris-
tics of these cells (Fig. 1B). As for the protein analysis 
(Fig. 1C), the demethylating compound had significantly 
induced CD146 expression in all analysed cell lines. This 
effect was clearly visible in the epithelial lines with very 
low basal expression of CD146, as well as in the MDA-
MB-231 cells, where the relatively high basal expression 
was still apparently inducible, in accordance with the 
data obtained at the mRNA level. Altogether, this data 
suggest that epigenetic silencing plays an important role 
in the control of CD146 expression in breast cancer cells 
with epithelial characteristics (MCF7 and T47D), whereas 
in mesenchymal breast cancer cell line (MDA-MB-231) 
expression of CD146 is apparently not fully unleashed 
and still partially trapped by the epigenetic mechanism.
The effect of 5-aza-2-deoxycytidine on induction of the 
mesenchymal profile
To determine if CD146 gene expression increase is 
associated with a mesenchymal profile induction, we 
analysed the influence of an epigenetic modifier, 5 aza-
2-deoxycytidine (10 µM), on expression panel of mesen-
chymal markers: Slug (SNAI2), Twist1 (TWIST1), Zeb1 
(ZEB1), Snail (SNAI1), N-cadherin (CADHERIN 2), 
Vimentin (VIM), matrix metalloproteinase-2 (MMP2) 
and matrix metalloproteinase-9 (MMP9), and an epithelial 
marker E-cadherin (CADHERIN 1). The mesenchymal 
markers subjected to this analysis were selected based on 
the expression correlation studies performed in breast 
cancer patients (Table 2). As shown in Fig. 2A, treat-
ment of breast cancer cell lines with the demethylating 
agent resulted in gene expression changes at the mRNA 
level for several mesenchymal markers, such as SANI1, 
Figure 1. The effect of demethylating agent, 5-aza-2-deoxycyti-
dine, on expression of CD146 in breast cancer cell lines at the 
mRNA and protein level. 
(A) upper panel: Representative results of RT-PCR analysis for 
CD146 expression in breast cancer cell lines cultured in the ab-
sence and presence of 10 μM 5-aza-2-deoxycytidine for 144 h. 
Lower panel: Graph presenting densitometry analysis of three 
independent experiments. Mean values ± S.E.M. (standard error of 
the mean) after normalization to HPRT signal are shown. **p<0.01, 
by student’s t-test, p-value between 0.05 and 0.1 was considered 
as an indication of a trend. (B) upper panel: Representative re-
sults of RT-PCR analysis for CD146 expression in MDA-MB-231 
breast cancer cell line cultured in the absence and presence 
of 10 μM 5-aza-2-deoxycytidine for 144 h. Lower panel: Graph 
presenting densitometry analysis of three independent experi-
ments. Mean values ± S.E.M. after normalization to HPRT signal are 
shown. **p<0.01, by student’s t-test. (C) Western blot analysis of 
CD146 protein expression level in breast cancer cell lines cultured 
in the absence and presence of 10 μM 5-aza-2-deoxycytidine for 
144 h. Representative experiment of three independent ones is 
shown. 
Figure 2.  The effect of demethylating agent, 5-aza-2-deoxycy-
tidine, on expression of selected mesenchymal markers and E-
cadherin, in breast cancer cell lines at the mRNA and protein 
level.
(A) Representative results of RT-PCR analysis of mesenchymal 
markers and E-cadherin expression in breast cancer cell lines 
cultured in the absence and presence of 10 μM 5-aza-2-deoxy-
cytidine for 144 h. (B) Densitometric quantification of mRNA ex-
pression of selected EMT-related genes in breast cancer cell lines 
cultured in the absence and presence of 10 μM 5-aza-2-deoxycy-
tidine for 144 h. Data are shown as mean values ± S.E.M. of 3 in-
dependent experiments after normalization to respective HPRT1 
levels. **p<0.01, by student’s t-test, p-value between 0.05 and 0.1 
was considered as an indication of a trend. (C) Western blot analy-
sis of N-cadherin, E-cadherin and Vimentin protein expression in 
breast cancer cell lines cultured in the absence and presence of 
10 μM 5-aza-2-deoxycytidine for 144 h. Representative experiment 
of two independent ones is shown. 
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SNAI2, TWIST1, MMP2, MMP9 and CADHERIN 2, 
whereas densitometry analysis of three independent ex-
periments (Fig. 2B) confirmed significant changes/or in-
dication of the trend for SNAI1 (T47D, MDA-MB-231), 
TWIST1 (T47D, MDA-MB-231), SNAI2 (MCF7), 
CADHERIN 2 (MDA-MB-231), MMP2 (MCF7, T47D, 
MDA-MB-231) and MMP9 (MCF7). As for the epithe-
lial marker, CADHERIN 1, the basal mRNA expression 
was high in cell lines with epithelial characteristics and 
low in MDA-MB-231. Of note, in all three independent 
experiments, we observed an increase of CADHERIN 1 
expression at the mRNA level in the MDA-MB-231 
cells, regardless of the induction of mesenchymal marker 
expression (SNAI1 and TWIST1) in these cells, which 
are the well known transcription factors inhibiting the 
CADHERIN 1 gene promoter. Concerning protein 
analysis, E-cadherin was not visibly induced in MDA-
MB-231, opposite to N-cadherin, whose expression was 
reproducibly enhanced after treatment with 5-aza-2-de-
oxycytidine, in two independent experiments. As for vi-
mentin, it was apparently expressed only in the MDA-
MB-231 cell line and not further induced by treatment 
with 5-aza-2-deoxycytidine. Undoubtedly, however, the 
fact that an epigenetic mechanism appears to control ex-
pression of such an important oncogene in breast cancer 
seems to be of high importance. To further determine if 
5-aza-2-deoxycytidine, resulting in CD146 induction, may 
as well trigger the changes in morphology of epithelial 
breast cancer cells and/or induce the protein expression 
changes at the level of a single cell, we performed an 
immunofluorescence analysis of E-cadher-
in and Vimentin in the MCF7 and T47D 
cells cultured for 6 days with and without 
5-aza-2-deoxycytidine. As determined in 
Fig. 3, we neither observed an apparent 
changes in cell morphology, nor, in ac-
cordance with the Western blot results, an 
alteration in the E-cadherin and Vimentin 
cell content. 
The analysis of CD146 gene promoter 
methylation in breast cancer cell lines
Since presence of the CpG island in 
CD146 gene promoter has been already 
described and its proper location reported 
by our group (Kocemba et al., 2016), we 
subjected the CD146 promoter region, 
including the CpG island encompassing 
the transcriptional start site in exon 1, to 
methylation analysis using direct bisulfite-
sequencing (BS) of PCR products. DNA 
isolated from human fibroblasts and in vitro 
Figure 3. The effect of demethylating agent, 5-aza-2-deoxycyti-
dine, on cell morphology and expression of E-cadherin and Vi-
mentin in epithelial breast cancer cell lines (MCF7 and T47D), 
assessed by immunofluorescence. 
Immunofluorescence staining of E-cadherin and vimentin in breast 
cancer cell lines (MCF7 an dT47D) cultured in the absence and 
presence of 10 μM 5-aza-2-deoxycytidine for 144 h.
Figure 4. Pattern of CpG island methylation in 
selected region of the CD146 gene promoter. 
Schematic representation of the CpG island area 
analyzed in the CD146 gene promoter. Arrows 
mark the positions of bisulfite sequencing prim-
ers. Each of the CpG dinucleotides is presented 
as a vertical line. The figure shows a representa-
tive fragment containing representative 22 CpG 
sites out of 50 analyzed ones. Electropherograms 
of bisulfite modified DNA from a representa-
tive CD146 gene promoter CpG island fragment 
in MCF7, T47D, MDA-MB-231 is shown together 
with DNA isolated from human fibroblasts and in 
vitro methylated DNA used as an unmethylated 
and methylated control DNA, respectively. White 
circles indicate unmethylated CpG sites, black cir-
cles indicate the presence of methylation in CpG 
sites detected by direct Sanger sequencing of the 
bisulfite-modified DNA.
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methylated DNA was modified and subsequently used in 
BS sequencing as unmethylated and methylated control, 
respectively, to validate our experimental set-up. BS anal-
ysis revealed that two (MCF7 and MDA-MB-231) out of 
the three breast (Fig. 4) cancer cell lines tested (MCF7, 
T47D and MDA-MB-231) displayed hypermethylation of 
CpG island in the CD146 promoter area, whereas T47D 
was methylation-free. Notably, BS analysis revealed het-
erogeneous methylation in MCF7 and MDA-MB-231, 
suggesting clonal variation in the methylation pattern 
of the CpG island area in these cell lines. Importantly, 
aberrant methylation detected in the CpG island of the 
CD146 gene (Fig. 4) was present in the promoter area 
encompassing exon one, the region reported previously 
as crucial for epigenetic silencing of gene expression 
(Brenet et al., 2011). 
DISCUSSION
To our knowledge, this is the first study showing 
methylation of the CD146 promoter region in breast 
cancer cells, and concomitantly suggesting that an epi-
genetic mechanism may be important in expression con-
trol of this relevant metastasis related-oncogene. In our 
previous paper, using prostate cancer cell lines, we have 
shown that the CD146 gene is induced by a demethylat-
ing compound, 5 aza-2-deoxycytidine, however, analysis 
of the CpG island region in those cells did not confirm 
presence of promoter methylation (Dudzik et al., 2019). 
Of note, the link between epigenetics and expression 
of the CD146 gene was reported previously in prostate 
cancer patients but the authors of that study incorrectly 
localized the CpG island in the CD146 gene promoter 
(Liu et al., 2008), and in consequence misinterpreted the 
results suggesting, contrary to the dogma, that presence 
of the CpG island methylation correlates with increase in 
the CD146 gene expression in prostate cancer cells (Liu 
et al., 2008). This mistake was pointed out in a Letter to 
the Editor published in The Prostate in 2016 (Kocemba 
et al., 2016), also determining proper localization of the 
CpG island in the CD146 gene promoter (Kocemba et 
al., 2016). So far, in literature, the relation between DNA 
methylation in the promoter area (regardless of presence 
of a CpG island) and gene expression inactivation has 
been well confirmed (Han et al., 2011; Smith & Meiss-
ner, 2013). It has been verified that canonical promoter 
methylation is associated with expression of imprinted 
genes, the process of X chromosome inactivation and 
tissue specific gene regulation (Smith & Meissner, 2013; 
Urbano et al., 2019). On the other hand, CpG islands 
observed around transcription start sites in 50% of gene 
promoters are methylation free in non-cancerous cells, 
regardless of the expression state of the gene of inter-
est (Jones, 2012). However, de novo hypermethylation 
of canonical CpG islands has been observed in cancer 
cells in association with inactivation of gene expression 
(Jones & Baylin, 2007). Although we observed the CpG 
island methylation of the CD146 promoter in 2 out of 
3 analysed breast cancer cell lines, it does not have to 
be the only and unique methylated region which controls 
CD146 expression, since in the T47D breast cancer cell 
line and three prostate cancer cell lines published previ-
ously (Dudzik et al., 2019), the CD146 expression was 
induced by demethylating treatment, while the analysed 
CpG island was methylation free. Importantly, recent 
studies revealed that methylation in the upstream and 
downstream CpG island shores may inhibit gene tran-
scription in cancer cells, whereas the CpG island itself 
can remain methylation free (Rao et al., 2013; Irizarry et 
al., 2009). Even more, in a recent publication, Skvort-
sova et al. revealed that methylation present in the CpG 
island shores, particularly in the breast cancer cells, is 
involved in transcriptional silencing of gene expression. 
These data clearly confirm that promoter methylation in 
silenced genes in cancer does not have to be confined 
only to the CpG island (Skvortsova et al., 2019). To ver-
ify exactly which promoter part must be demethylated 
to unleash the CD146 expression would be definitely of 
high importance. Whereas overexpressed CD146 is con-
sidered to be oncogenic in breast cancer cells, as report-
ed by independent studies (Zeng et al., 2012; de Krui-
jff et al., 2018; Garcia et al., 2007; Zabouo et al., 2009; 
Imbert et al., 2012), the methylation-based silencing of 
its expression in these cells seems to be quite surpris-
ing. According to our hypothesis, at the beginning of the 
disease CD146 may be targeted for aberrant promoter 
methylation/or it has been already methylated in con-
sequence of tissue specific epigenetic silencing, whereas 
the loss of methylation in advanced tumour unleashes 
CD146 expression, leading to metastasis. The fact that 
CD146-dependent induction of a mesenchymal profile 
has been already described in the literature (Imbert et al., 
2012; Zeng et al., 2012; Zabouo et al., 2009) allows us to 
speculate that increase in expression of mesenchymal re-
lated genes may result from CD146 induction, triggered 
by an epigenetic modifier. On the other hand, we can-
not exclude that the epigenetic modifier, in parallel to 
the increase in CD146 expression, directly induces mes-
enchymal profile in the breast cancer cell lines, as the 
EMT induction in consequence of 5-aza-2-deoxycytidine 
application has been already reported for breast cancer 
cells (Su et al., 2018). Definitely, more research is needed 
to elucidate the independent role of CD146, expression 
triggered by an epigenetic modifier, in EMT induction 
in breast cancer cells. Interestingly, in a mesenchymal 
cell line (MDA-MB-231), we observed an increase in the 
epithelial marker, E-cadherin, at the mRNA level, which 
can be the direct consequence of demethylating agents, 
since epigenetic silencing of E-cadherin expression by 
aberrant promoter methylation has been reported previ-
ously in cancer cells of mesenchymal characteristics and 
what is more, exactly in MDA-MB-231. Thus, it can be 
concluded that our results for CADHERIN 1 in MDA-
MB-231 simply indicate a proper experimental setup for 
the demethylating treatment. It is also important to men-
tion that Imbert et al., after overexpression of CD146 
in the MCF7 cell line, reported lack of alteration in 
TWIST1, SNAI1, MMP2 and MMP9 expression and an 
increase in CADHERIN 2 and VIM (Imbert et al., 2012), 
whereas changes in the mesenchymal markers’ profile 
were completely different in our current study, which is 
most probably the consequence of combined action of 
CD146 and the demethylating agent. Undoubtedly, how-
ever, showing that expression of CD146 is controlled 
by an epigenetic mechanism seems to be the most im-
portant message from our study. Moreover, our analysis 
also suggests coexistence of cells with methylated and 
unmethylated CD146 gene promoter, which indicates 
that alterations in the CD146 gene promoter methylation 
may reflect the process of clonal selection during breast 
cancer progression. In this context, the aspect of epige-
netic control of CD146 expression takes on a particular 
significance in research centred on application of 5-aza-
2-deoxycytidine in treatment of breast cancer patients, 
and should be considered in planning therapy combined 
with epigenetic modifiers. It is especially important, since 
this kind of therapy for breast cancer patients has been 
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currently investigated (Connolly et al., 2017). Our data 
undoubtedly requires further verification to potentially 
reveal the scenario of methylation changes in the CD146 
gene promoter during development of breast cancer pro-
gression, as we cannot exclude that CD146 acts as a tu-
mour suppressor at the initial stage of carcinogenesis, as 
suggested by the study of Shih and others (Shih et al., 
1997), and turn into an oncogene in the advance stage, 
when the transcriptional profile of cancer cells is signifi-
cantly altered. Overall, our study provides strong basis 
for further research on epigenetic regulation of CD146, 
which can significantly contribute to novel therapies 
and/or development of DNA methylation-based assay 
for sensitive detection of breast cancer cells.
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